S&P Futures
3,862.50 +14.25 (+0.37%) Dow Futures
31,174.00 +161.00 (+0.52%) Nasdaq Futures
11,924.25 +44.00 (+0.37%) Russell 2000 Futures
1,737.20 +8.60 (+0.50%) Crude Oil
99.48 +0.95 (+0.96%) Gold
1,737.80 +1.30 (+0.07%)
Evolus, Inc. (EOLS)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 12.39 |
| Open | 12.30 |
| Bid | 12.68 x 1100 |
| Ask | 12.90 x 1400 |
| Day's Range | 12.30 - 13.03 |
| 52 Week Range | 5.06 - 14.34 |
| Volume | |
| Avg. Volume | 513,251 |
| Market Cap | 723.593M |
| Beta (5Y Monthly) | 2.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.30 |
| Earnings Date | Aug 02, 2022 - Aug 08, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.38 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for EOLS
Related Research
- Evolus, Inc. Common StockDaily – Vickers Top Buyers & Sellers for 09/01/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat10 months agoArgus Research
- Benzinga
Needham Is Bullish On This Botox Equivalent Aesthetics Company
Needham initiated coverage on Evolus Inc (NASDAQ: EOLS) with a price target of $18.00 (43% upside) and a Buy rating. Evolus is a pure-play aesthetics company focused on growing the presence of Jeuveau, its new neurotoxin product, in the approximately $3 billion global wrinkle treatment market. Jeuveau is a prescription medicine injected into muscles to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines). Needham views Evolus as an emerging star in aesthetics
- Simply Wall St.
Investors in Evolus (NASDAQ:EOLS) have unfortunately lost 15% over the last three years
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
- Zacks
Does Evolus, Inc. (EOLS) Have the Potential to Rally 28% as Wall Street Analysts Expect?
The mean of analysts' price targets for Evolus, Inc. (EOLS) points to a 28.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
